Moving targets: cell migration inhibitors as new anti-inflammatory therapies

The pharmaceutical industry has targeted various types of molecules to subdue inflammatory diseases. Drugs that disrupt cell migration appear particularly promising in clinical trials and in many animal models of inflammatory disease. Cell migration inhibitors not only interfere with migration of cells to a tissue, but also can affect other necessary processes such as mediator release and angiogenesis. However, the question is whether drugs that target adhesion molecules or chemoattractant receptors will prove superior to drugs that target other molecular types. This review proclaims the virtues of targeting cell migration–related molecules for development of new anti-inflammatory and anti-tumor based drugs. It is likely that cell migration inhibitors will transform the way in which many human inflammatory diseases and cancers are treated.

[1]  H. Soto,et al.  CCL27–CCR10 interactions regulate T cell–mediated skin inflammation , 2002, Nature Medicine.

[2]  J. Sullivan CC chemokine receptor 5 and renal-transplant survival , 2001, The Lancet.

[3]  Pixu Liu,et al.  An Anti-inflammatory Function for the Complement Anaphylatoxin C5a-binding Protein, C5L2* , 2005, Journal of Biological Chemistry.

[4]  R. Gladue,et al.  Current status of CCR1 antagonists in clinical trials , 2007 .

[5]  D. Piwnica-Worms,et al.  CXCR 4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004 .

[6]  Silvano Sozzani,et al.  Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation , 2000 .

[7]  W Newman,et al.  Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. , 1996, The Journal of clinical investigation.

[8]  H. Kataoka,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. , 1998, Journal of immunology.

[9]  A. Proudfoot Chemokine receptors: multifaceted therapeutic targets , 2002, Nature Reviews Immunology.

[10]  L. Yang,et al.  A functional promoter polymorphism in monocyte chemoattractant protein‐1 is associated with psoriasis , 2007, International journal of immunogenetics.

[11]  D. Rader,et al.  Val64Ile Polymorphism in the C-C Chemokine Receptor 2 Is Associated With Reduced Coronary Artery Calcification , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[12]  Hiromu Ito,et al.  Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model , 2007, The Journal of experimental medicine.

[13]  R. Alon,et al.  Immune cell migration in inflammation: present and future therapeutic targets , 2005, Nature Immunology.

[14]  I. Forbes,et al.  Targeted replacement of rodent CCR2 with the human orthologue CCR2B: A mouse model for in vivo analysis of human target‐selective small molecule MCP‐1 receptor antagonists , 2002 .

[15]  D. Duda,et al.  CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2006, Haematologica.

[16]  M. Cybulsky,et al.  Getting to the site of inflammation: the leukocyte adhesion cascade updated , 2007, Nature Reviews Immunology.

[17]  Diego G. Silva,et al.  Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA , 2007, Nature.

[18]  L. Hassman,et al.  A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation , 2006, Proceedings of the National Academy of Sciences.

[19]  T. Yamamura,et al.  Cutting Edge: Human Th17 Cells Are Identified as Bearing CCR2+CCR5− Phenotype1 , 2007, The Journal of Immunology.

[20]  A. Tager,et al.  A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis , 2006, The Journal of experimental medicine.

[21]  A. Menter,et al.  Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis , 2008, The British journal of dermatology.

[22]  E. Kostenis,et al.  Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation. , 2006, Current topics in medicinal chemistry.

[23]  C. McKerlie,et al.  C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a , 2007, Nature.

[24]  M. Parmentier,et al.  Allosteric Transinhibition by Specific Antagonists in , 2007 .

[25]  C. Mackay,et al.  Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. , 1996, Gastroenterology.

[26]  Trevor T. Hansel,et al.  Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases , 2007, Nature Reviews Drug Discovery.

[27]  Alnawaz Rehemtulla,et al.  CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature , 2007, Proceedings of the National Academy of Sciences.

[28]  C. Mackay,et al.  Follicular B helper T cells in antibody responses and autoimmunity , 2005, Nature Reviews Immunology.

[29]  C. Geula,et al.  Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease , 2007, Nature Medicine.

[30]  Jacques P. Brown,et al.  Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[31]  D. Craik,et al.  Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. , 1998, Journal of medicinal chemistry.

[32]  C. Rommel,et al.  PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? , 2007, Nature Reviews Immunology.

[33]  C. Mackay,et al.  Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2 , 2008, Immunology and cell biology.

[34]  A. Mantovani,et al.  Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin , 2005, The Journal of experimental medicine.

[35]  J. Minna,et al.  High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. , 2006, Cancer research.

[36]  H. Sarau,et al.  A Potent and Selective Nonpeptide Antagonist of CXCR2 Inhibits Acute and Chronic Models of Arthritis in the Rabbit1 , 2002, The Journal of Immunology.

[37]  B. Aronow,et al.  Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. , 2006, The Journal of clinical investigation.

[38]  Jens V Stein,et al.  How chemokines invite leukocytes to dance , 2008, Nature Immunology.

[39]  Emilio Hirsch,et al.  Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis , 2005, Nature Medicine.

[40]  D. Rader,et al.  Val 64 Ile Polymorphism in the C-C Chemokine Receptor 2 Is Associated With Reduced Coronary Artery Calcification , 2002 .

[41]  Antonio Alcami,et al.  Viral mimicry of cytokines, chemokines and their receptors , 2003, Nature Reviews Immunology.

[42]  K. Pienta,et al.  The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer* , 2008, Journal of Biological Chemistry.

[43]  S. O. Smith,et al.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Friend,et al.  The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[46]  T. Beaty,et al.  Sequence variants of the gene encoding chemoattractant receptor expressed on Th2 cells (CRTH2) are associated with asthma and differentially influence mRNA stability. , 2004, Human molecular genetics.

[47]  D. F. Barber,et al.  PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus , 2005, Nature Medicine.

[48]  H. Spring,et al.  Chemokines direct endothelial progenitors into tumor neovessels. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Minna,et al.  High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. , 2006 .

[50]  D. McDermott,et al.  CCR5 deficiency increases risk of symptomatic West Nile virus infection , 2006, The Journal of experimental medicine.

[51]  C. Rommel,et al.  PI3Kγ inhibition: towards an 'aspirin of the 21st century'? , 2006, Nature Reviews Drug Discovery.

[52]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[53]  T. Issekutz,et al.  Blockade of Chemokine Receptor CXCR3 Inhibits T Cell Recruitment to Inflamed Joints and Decreases the Severity of Adjuvant Arthritis1 , 2007, The Journal of Immunology.

[54]  E. Maris,et al.  Two Sides of the Same Coin , 2010, Psychological science.

[55]  A. Fryer,et al.  Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. , 2005, The Journal of clinical investigation.

[56]  Søren B. Padkjær,et al.  Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies , 2006, Nature Biotechnology.

[57]  B. Brenner,et al.  Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. , 2002, Journal of the American Society of Nephrology : JASN.

[58]  P. Johnston,et al.  HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells , 2007, Oncogene.

[59]  A. Viola,et al.  Chemokines and their receptors: drug targets in immunity and inflammation. , 2008, Annual review of pharmacology and toxicology.

[60]  Y. Shimizu,et al.  Transgenic mouse expressing human CCR5 as a model for in vivo assessments of human selective CCR5 antagonists. , 2005, European journal of pharmacology.

[61]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[62]  Michael G. Johnson,et al.  Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. , 2006, Cancer research.

[63]  D. Jarrossay,et al.  Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells , 2007, Nature Immunology.

[64]  P. Ward,et al.  Role of C5a in inflammatory responses. , 2005, Annual review of immunology.

[65]  J. Cyster,et al.  Finding a way out: lymphocyte egress from lymphoid organs , 2007, Nature Immunology.

[66]  C. Mackay,et al.  T-cell function and migration. Two sides of the same coin. , 2000, The New England journal of medicine.

[67]  W L Stanford,et al.  Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. , 2000, Science.

[68]  R. Cholera,et al.  Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection , 2005, The Journal of experimental medicine.

[69]  Albert Zlotnik Chemokines and cancer , 2006, International journal of cancer.

[70]  Michael G. Johnson,et al.  Antagonism of CXCR 3 Inhibits Lung Metastasis in a Murine Model of Metastatic Breast Cancer , 2006 .

[71]  V. Kuchroo,et al.  TH-17 cells in the circle of immunity and autoimmunity , 2007, Nature Immunology.

[72]  R. Strieter,et al.  CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer , 2006, The Journal of experimental medicine.

[73]  Eiji Sakurai,et al.  An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice , 2003, Nature Medicine.

[74]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[75]  C. Mackay,et al.  Chemokines: immunology's high impact factors , 2001, Nature Immunology.

[76]  M. Tabrizi,et al.  Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. , 2004, Chest.

[77]  G. Lichtenstein Treatment of Ulcerative Colitis With a Humanized Antibody to the α4β7 Integrin , 2006 .

[78]  G. Trainor,et al.  Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. , 2005, Journal of medicinal chemistry.

[79]  J. Wheeler,et al.  Assessing Theoretical Risk and Benefit suggested by Genetic Association Studies of CCR5: Experience in a Drug Development Programme for Maraviroc , 2007, Antiviral therapy.

[80]  M. Smit,et al.  Human CXCR2 (hCXCR2) takes over functionalities of its murine homolog in hCXCR2 knockin mice , 2005, European journal of immunology.

[81]  D. Kemeny,et al.  Inhibition of Th1- and Th2-Mediated Airway Inflammation by the Sphingosine 1-Phosphate Receptor Agonist FTY720 , 2003, The Journal of Immunology.

[82]  Timothy A. Springer,et al.  Therapeutic antagonists and conformational regulation of integrin function , 2003, Nature Reviews Drug Discovery.

[83]  Richard P. Harvey,et al.  Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7 , 2007, Proceedings of the National Academy of Sciences.

[84]  C. Mackay,et al.  Functional roles for C5a receptors in sepsis , 2008, Nature Medicine.

[85]  D. Piwnica-Worms,et al.  CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004, Cancer Research.

[86]  B. Moser,et al.  Chemokine Biology — Basic Research and Clinical Application , 2006 .

[87]  Joerg Kallen,et al.  Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site , 2001, Nature Medicine.

[88]  P. Zipfel,et al.  Complement and diseases: defective alternative pathway control results in kidney and eye diseases. , 2006, Molecular immunology.

[89]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[90]  Kevin Wei,et al.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development , 2006, The Journal of experimental medicine.

[91]  R. Geha,et al.  CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. , 2002, The Journal of clinical investigation.

[92]  J. Stockman,et al.  Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis , 2008 .

[93]  J. Lötvall,et al.  Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. , 1999, Journal of immunology.

[94]  C. Mackay,et al.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. , 1998, The Journal of clinical investigation.

[95]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[96]  A. Rot,et al.  CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells , 2007, The Journal of experimental medicine.

[97]  J. Bach,et al.  The effect of infections on susceptibility to autoimmune and allergic diseases. , 2002, The New England journal of medicine.

[98]  C. Mackay,et al.  Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. , 1997, The Journal of clinical investigation.

[99]  E. Butcher,et al.  Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking , 2008, Nature Immunology.

[100]  F. Breedveld,et al.  A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.